Call for papers 2018

Content scope and submission requirements for thematic series

Theme 1: Emerging Immunotherapeutic Agents
Theme is within the scope of the Clinical/Translational Cancer Immunotherapy section 

Original research or review articles articles submitted on the topic of Emerging Immunotherapeutic Agents should address basic biophysical properties, synthesis and manufacturing, novel mechanisms of action, preclinical safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and regulatory information on new immunotherapy agents and their combinations

Papers should focus on new agents that are intended to begin, or are undergoing, clinical development, but may also include molecules that are in advanced clinical development or approved. New immunotherapy agents include small molecules, cell therapies, gene therapies, antibodies, bispecific and bifunctional molecules, and other novel chemistries

Papers should be primarily on relevant, publishable original research in IMPDs (Europe) and INDs (USA). We also welcome the submission of review articles, white papers, or commentaries on emerging immunotherapeutic agents in development after inquiry and approval by the editors.  

Requirements for submissions:
•    Structured abstract: 350 words or less
•    Main text: 3,000-5,000 words 
•    Figures/Tables: minimum of 3-4 figures or tables
•    References: 50-75 references on average
•    Cover Letter: Include intention to submit in response to 
     Emerging Immunotherapeutic Agents call for papers

Both themes below are within the  scope of the Clinical Trials Monitor section

Theme 2: New Regulatory Approvals in Cancer Immunotherapy
Into the clinic
This format within the series will review newly approved immunotherapies, highlighting the drug development process for the agent and indication, including any important biomarkers. It will also provide guidance about how the newly approved drug fits into the standard of care as it enters the clinic. These pieces will be written by leading immunotherapy experts in disease-specific areas, and should help inform the development of clinical practice guidelines by SITC, NCCN, and ASCO.

Regulatory approval summary
This format will include approval summaries from regulatory agencies around the world as new immunotherapies are approved for standard clinical use.

Requirements for submissions:
•    Structured abstract: 350 words or less
•    Main text: 4,000-5,000 words 
•    Figures/Tables: minimum of 1-2 figures or tables
•    References: 50-75 references on average
•    Cover Letter: Include intention to submit in response to      
     Clinical Trials  Monitor call for papers

Theme 3: Challenges in Clinical Management
Beyond the numbers
This educational feature puts cancer immunotherapy into broad context. Subject matter may include a discussion of statistical considerations and perspectives essential for understanding results of pivotal clinical trials, clinical trial design and data analysis issues particularly relevant to cancer immunotherapy, and unresolved issues related to reduction to practice (toxicity management or issues related to access to novel immunotherapies (adoptive T cell therapy/CAR T cells).

Requirements for submissions:
•    Structured abstract: 350 words or less
•    Main text: 4,000-5,000 words 
•    Figures/Tables: minimum of 1-2 figures or tables
•    References: 50-75 references on average
•    Cover Letter: Include intention to submit in response to      
     Clinical Trials  Monitor call for papers

Full submission guidelines for article types may be found at https://jitc.biomedcentral.com/submission-guidelines.

Questions may be submitted to JITCEditor@sitcancer.org.

Submission Deadline

Friday, March 2, 2018 – 4pm CT

 
JITC logo

Advertisement